Abstract: Disclosed embodiments include a CNC machine comprising: (i) a laser head; (ii) a housing defining an interior space bounded by an interior floor, interior walls, and an openable lid that has a lid camera assembly with a camera for capturing images of the interior space; (iii) a material bed configured to support material placed within the interior space; (iv) a first material passthrough opening on a first side of the housing, wherein the first material passthrough opening comprises a curtain, wherein the curtain is arranged to block laser light from exiting through the first material passthrough opening while material is inserted through the first material passthrough opening; and (v) an exhaust port configured to route fumes from within the interior space to an air filter separate from the CNC machine.

Abstract: A turbine engine includes an engine core extending along an engine centerline and includes a compressor section, a combustor, and a turbine section in serial flow arrangement. A temperature sensor is provided within the engine and configured to detect a gas temperature within the engine core. A set of blades is circumferentially arranged in the turbine section. A blade in the set of blades includes an outer wall bounding an interior, a cooling conduit within the interior, and a plurality of film holes fluidly coupled to the cooling conduit.

Abstract: A computer numerically controlled machine may include a source configured to deliver an electromagnetic energy to at least one location within an interior space of the computer-numerically-controlled machine. The electromagnetic energy may have a first range of wavelengths from a visible spectrum. An enclosure defining at least a portion of the interior space of the computer numerically controlled machine may include a transparent portion configured to filter the first range of wavelengths associated with the electromagnetic energy. Moreover, the transparent portion may reflect and/or transmit at least a second range of wavelengths from the visible spectrum not associated with the electromagnetic energy such that the transparent portion of the enclosure exhibits a first color corresponding to the second range of wavelengths.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: A multi-body self-propelled device can include a drive body and a coupled head. The drive body can include a spherical housing and an internal drive system within the spherical housing to propel the multi-body self-propelled device. The drive body can further include a magnet support assembly comprising a rotating portion including a plurality of magnets and a stationary portion comprising one or more magnets. The drive body can further include a yaw motor to drive the rotating portion of the magnet support assembly. The coupled head can include (i) a corresponding rotating portion comprising a plurality of magnets in magnetic interaction, through the spherical housing, with the plurality of magnets of the magnet support assembly, and (ii) a corresponding stationary portion comprising one or more magnets in magnetic interaction with the one or more magnets of the magnet support assembly.

Abstract: The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: A multi-body self-propelled device can include a drive body and a coupled head. The drive body can include a spherical housing and an internal drive system within the spherical housing to propel the multi-body self-propelled device. The drive body can further include a magnet holder coupled to the internal drive system to hold a first set of magnetic elements. The coupled head can include a base plate to hold a second set of magnetic elements to create a magnetic interaction with the first set of magnetic elements through the spherical housing. The coupled head can further include a housing structure and a yaw motor that rotates the housing structure independently in relation to the base plate and the drive body.

Abstract: A multi-body self-propelled device can include a drive body and a coupled head. The drive body can include a spherical housing and an internal drive system within the spherical housing to propel the multi-body self-propelled device. The drive body can further include a magnet support assembly comprising a rotating portion including a plurality of magnets and a stationary portion comprising one or more magnets. The drive body can further include a yaw motor to drive the rotating portion of the magnet support assembly. The coupled head can include (i) a corresponding rotating portion comprising a plurality of magnets in magnetic interaction, through the spherical housing, with the plurality of magnets of the magnet support assembly, and (ii) a corresponding stationary portion comprising one or more magnets in magnetic interaction with the one or more magnets of the magnet support assembly.

Abstract: The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical formulation comprising less than about 5% w/v sodium deoxycholate maintained at a pH sufficient to substantially inhibit precipitation of the sodium deoxycholate. Also disclosed herein, are methods for inhibiting precipitation of sodium deoxycholate in an aqueous solution comprising less than about 5% w/v of sodium deoxycholate, said method comprising maintaining pH of the solution of from at least about 8.0 to about 8.5.

Abstract: The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4% w/v to less than about 2% w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.